CollPlant’s Innovative Human Collagen for Wound Care

CollPlant, Ltd of Rehovot, Israel, is a developer and manufacturer of human collagen-based medical products designed to treat chronic wounds including diabetic foot care, pressure ulcers and wounds. Its product, called Vergenix FG, is based on a human collagen produced in tobacco plants. It is presently part of a clinical trial in Israel.

Officials describe “Vergenix FG is an advanced gel formulation based on rhCollagen for the treatment of deep tunneled and / or undermined wounds including wounds with irregular geometry. This injectable advanced gel formulation provides a pure human collagen scaffold that fills the wound bed and provides maximal contact with the surrounding tissue.”

Principal objective of the trial is to evaluate the safety of the product and its level of performance on patients who are suffering from chronic wounds to their lower limbs. Investigators will determine the effectiveness of the treatment by measuring the percentage of wound closure.

The trial, which researchers expect will last for several months, will take place at three wound clinics in Israel. Twenty patients suffering from lower limb chronic wounds will participate. Doctors will give each patient a one-time treatment with the product and then monitor their progress for four weeks.

CollPlant CEO Yehiel Tal said, “We are very pleased to be commencing the clinical trial of Vergenix FG which is based on a unique technology that has the potential to significantly improve the outcomes for patients with lower limb chronic wounds. The trial is a major milestone in our plan to commercialize the company’s products in global markets. We are now preparing to apply for the CE Mark for marketing the product in Europe”